Mario de la Fuente Revenga

The paper develops a non-radioactive method to measure 5-HT2A receptor activation in the mouse brain via IP1 detection and correlates it with behavioral and pharmacological responses.

This paper identifies a non-enzymatic HDAC inhibitor with anti-tumor and anti-psychedelic effects, showing reduced gene modulation compared to enzymatic inhibitors.

This study shows that a single dose of the psychedelic DOI causes long-lasting epigenetic and synaptic changes in mice, linked to antidepressant effects and potential risks for psychiatric disorders.